用于免疫力低下患者的康复血浆。

3区医学 Q2 Medicine

Current topics in microbiology and immunology Pub Date : 2024-08-09 DOI:10.1007/82_2024_272

Shmuel Shoham

{"title":"用于免疫力低下患者的康复血浆。","authors":"Shmuel Shoham","doi":"10.1007/82_2024_272","DOIUrl":null,"url":null,"abstract":"COVID-19 convalescent plasma (CCP) is an important therapeutic option for immunocompromised patients with COVID-19. Such patients are at increased risk for serious complications of infection and may also develop a unique syndrome of persistent infection. This article reviews the rationale for CCP utilization in immunocompromised patients and the evidence for its value in immunosuppressed patients with both acute and persistent COVID-19. Both historical precedence and understanding of the mechanisms of action of antibody treatment support this use, as do several lines of evidence derived from case series, comparative studies, randomized trials, and systematic reviews of the literature. A summary of recommendations from multiple practice guidelines is also provided.","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Convalescent Plasma for Immunocompromised Patients.\",\"authors\":\"Shmuel Shoham\",\"doi\":\"10.1007/82_2024_272\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"COVID-19 convalescent plasma (CCP) is an important therapeutic option for immunocompromised patients with COVID-19. Such patients are at increased risk for serious complications of infection and may also develop a unique syndrome of persistent infection. This article reviews the rationale for CCP utilization in immunocompromised patients and the evidence for its value in immunosuppressed patients with both acute and persistent COVID-19. Both historical precedence and understanding of the mechanisms of action of antibody treatment support this use, as do several lines of evidence derived from case series, comparative studies, randomized trials, and systematic reviews of the literature. A summary of recommendations from multiple practice guidelines is also provided.\",\"PeriodicalId\":11102,\"journal\":{\"name\":\"Current topics in microbiology and immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current topics in microbiology and immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/82_2024_272\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/82_2024_272","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

COVID-19 康复血浆（CCP）是免疫功能低下的 COVID-19 患者的重要治疗选择。这类患者发生严重感染并发症的风险增加，还可能出现独特的持续感染综合征。本文回顾了免疫功能低下患者使用 CCP 的理由，以及其在急性和持续性 COVID-19 免疫抑制患者中的价值证据。历史先例和对抗体治疗作用机制的理解都支持使用 CCP，而病例系列、比较研究、随机试验和系统性文献综述中的一些证据也支持使用 CCP。本报告还提供了多份实践指南的建议摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Convalescent Plasma for Immunocompromised Patients.

COVID-19 convalescent plasma (CCP) is an important therapeutic option for immunocompromised patients with COVID-19. Such patients are at increased risk for serious complications of infection and may also develop a unique syndrome of persistent infection. This article reviews the rationale for CCP utilization in immunocompromised patients and the evidence for its value in immunosuppressed patients with both acute and persistent COVID-19. Both historical precedence and understanding of the mechanisms of action of antibody treatment support this use, as do several lines of evidence derived from case series, comparative studies, randomized trials, and systematic reviews of the literature. A summary of recommendations from multiple practice guidelines is also provided.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current topics in microbiology and immunology 医学-免疫学

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.